华仁药业: insider trades · France · AMF SZSE:300110 FR FR · AMF Mcap 3.7Bn€
Discover the full directors' dealings record of 华仁药业, a listed equity based in France. Shares are quoted on FR FR, under the authority of AMF. Market capitalisation: €3.7bn. The latest transaction was disclosed on 6 February 2024 (Purchase). Among the most active insiders: 杨效东. All data is openly available.
Financial data FY ended December 2025 · cache
Income statement
Revenue 1.32 Bn€
Gross profit 489.5 M€ 37% margin
Net income −462.9 M€ -35.0% margin
Balance sheet & cash
Market cap 3.72 Bn€
Total debt 1.24 Bn€
Free Cash Flow 341.3 M€
Last declaration on 6 February 2024
Declarations 9 total
Executives ● Purchase18 SZSE
10,000 shares
SZSE:173000007310430660 · 6 Feb 2024
Ideal exit: 2 Nov 2024 (T+270) Executives ● Purchase18 SZSE
10,000 shares
SZSE:173000005476543360 · 26 Apr 2022
Ideal exit: 21 Jan 2023 (T+270) Executives ● Purchase14 SZSE
120,000 shares
SZSE:173000005470390200 · 25 Apr 2022
Ideal exit: 20 Jan 2023 (T+270) Executives ● Purchase29 SZSE
40,000 shares
SZSE:173000004737186000 · 27 Aug 2021
Ideal exit: 24 May 2022 (T+270) Executives ● Purchase29 SZSE
20,000 shares
SZSE:173000004552150700 · 8 Jul 2021
Ideal exit: 4 Apr 2022 (T+270) Executives ● Purchase22 SZSE
30,000 shares
SZSE:173000004512521800 · 23 Jun 2021
Ideal exit: 20 Mar 2022 (T+270) Executives ● Purchase29 SZSE
20,000 shares
SZSE:173000004497358720 · 17 Jun 2021
Ideal exit: 14 Mar 2022 (T+270) Executives ● Purchase22 SZSE
790,000 shares
SZSE:173000004486746800 · 11 Jun 2021
Ideal exit: 8 Mar 2022 (T+270) Executives ● Purchase22 SZSE
10,000 shares
SZSE:173000004478425860 · 10 Jun 2021
Ideal exit: 7 Mar 2022 (T+270)
